Skip to main content
Contact Us
Subscribe
E-Edition
57°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Athersys Inc
(NQ:
ATHX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 17, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Athersys Inc
< Previous
1
2
3
Next >
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
November 16, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
October 16, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
October 10, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Licenses its Animal Health Assets to Ardent Animal Health
October 03, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Director Jane Wasman Appointed Board Chair
October 02, 2023
From
Athersys, Inc.
Via
Business Wire
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
September 06, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
August 17, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
August 16, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
August 11, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Host Business Update Conference Call on August 9th
July 31, 2023
From
Athersys, Inc.
Via
Business Wire
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
June 01, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Restructures Debt with Supplier
May 23, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
May 18, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Participate in Three Upcoming Conferences
May 08, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
May 01, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
April 21, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
April 19, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
April 18, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Host Business Update Conference Call on April 20th
April 10, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 31, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Announces Successful Type B Meeting with the FDA
March 22, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Expands IP Protection with First New Patent for SIFU® Technology
February 28, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
February 14, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Host Business Update Conference Call on February 14th
February 02, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Participate in International Stroke Conference and BioProcess International
January 30, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
January 11, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Provides MultiStem Clinical Update
January 09, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Appoints Joseph Nolan to Its Board of Directors
January 05, 2023
From
Athersys, Inc.
Via
Business Wire
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
November 15, 2022
From
Athersys, Inc.
Via
Business Wire
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
November 11, 2022
From
Athersys, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.